{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:55Z","timestamp":1788675475779,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) are widely used in the treatment of metastatic renal cell carcinoma (RCC). Although hemorrhagic events are recognized adverse effects of these agents, intracranial hemorrhage is rare, and the safety of re-administration of VEGFR TKIs after central nervous system (CNS) hemorrhage remains unclear. We report a 52-year-old man with metastatic clear cell RCC who initially received first-line immunotherapy with ipilimumab and nivolumab, resulting in disease progression, followed by second-line sunitinib, which achieved a partial response. However, he subsequently developed sudden neurological deterioration, and brain imaging revealed multifocal cerebellar hemorrhages without evidence of brain metastasis; the absence of metastasis was confirmed by surgical and histopathological examination. After surgical management, complete radiologic resolution of the hemorrhage was confirmed 4 weeks postoperatively. Pazopanib was subsequently initiated based on the prior favorable response to VEGFR TKI therapy; however, recurrent cerebellar hemorrhage occurred within 4 weeks of rechallenge, leading to rapid clinical deterioration and death despite supportive care. This case highlights that VEGFR TKI\u2013associated intracranial hemorrhage can occur even in the absence of brain metastases and may recur with fatal consequences upon rechallenge. These findings suggest that early VEGFR TKI rechallenge (&amp;lt;1\u20132 months) after CNS hemorrhage may be unsafe, and that careful risk\u2013benefit assessment with an adequate waiting period is essential when considering re-administration.<\/jats:p>","DOI":"10.3389\/fonc.2026.1858153","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:01Z","timestamp":1780892581000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Recurrent intracranial hemorrhage without brain metastasis after VEGFR TKI rechallenge in metastatic renal cell carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Chang-Hoon","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School","place":["Jeonju, Republic of Korea"]},{"name":"Research Institute of Clinical Medicine, Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital","place":["Jeonju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Ri","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School","place":["Jeonju, Republic of Korea"]},{"name":"Research Institute of Clinical Medicine, Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital","place":["Jeonju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-89935-6_6","article-title":"Advances in the treatment of metastatic renal cell carcinoma","volume":"175","author":"Bergerot","year":"2018","journal-title":"Cancer Treat Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.044","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies: focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt307","article-title":"Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials","volume":"24","author":"Qi","year":"2013","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-039","article-title":"What is the risk of intracranial bleeding during anti-VEGF therapy","volume":"10","author":"Carden","year":"2008","journal-title":"Neuro Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S100204","article-title":"Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11912-012-0232-2","article-title":"The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients","volume":"14","author":"Sonpavde","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218221","article-title":"Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage","volume":"2017","author":"Miller-Patterson","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1515\/med-2021-0257","article-title":"Rivaroxaban triggered multifocal intratumoral hemorrhage of the cabozantinib-treated diffuse brain metastases: a case report and review of literature","volume":"16","author":"Chen","year":"2021","journal-title":"Open Med (Wars)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000534132","article-title":"Contemplation of the effect of nivolumab plus cabozantinib therapy on cerebral hemorrhage in patients with brain metastasis of renal cell carcinoma: a case report","volume":"16","author":"Sato","year":"2023","journal-title":"Case Rep Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-256100","article-title":"Convexal subarachnoid haemorrhage in a patient under pembrolizumab-lenvatinib combination therapy","volume":"16","author":"Simao","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12632","article-title":"Fatal tumoral hemorrhage from brain metastases of renal cell carcinoma after stereotactic radiotherapy and immune checkpoint inhibitor and vascular endothelial growth factor-targeted therapy combinations","volume":"7","author":"Iwasa","year":"2024","journal-title":"IJU Case Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55242","article-title":"Delayed postoperative intracerebral hemorrhage associated with oral multikinase inhibitor therapy for cancer: a case report","volume":"16","author":"Patel","year":"2024","journal-title":"Cureus"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1858153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:04Z","timestamp":1780892584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1858153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1858153"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1858153","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1858153"}}